BCG Vaccine and Neuroprotection in Parkinson's Disease Mice
Author Information
Author(s): Yong Jing, Lacan Goran, Dang Hoa, Hsieh Terry, Middleton Blake, Wasserfall Clive, Tian Jide, Melega William P., Kaufman Daniel L.
Primary Institution: Department of Molecular and Medical Pharmacology, University of California Los Angeles
Hypothesis
Can BCG vaccination provide neuroprotective effects in a mouse model of Parkinson's disease?
Conclusion
BCG vaccination partially preserved dopamine system integrity and limited microglial activation in a mouse model of Parkinson's disease.
Supporting Evidence
- BCG vaccination increased striatal dopamine levels by 16% compared to controls.
- BCG vaccination prevented the increase in activated microglia in the substantia nigra after MPTP treatment.
- Striatal DAT binding was significantly higher in BCG-vaccinated mice compared to unvaccinated controls.
Takeaway
Vaccinating mice with the BCG vaccine helped protect their brains from damage caused by a toxin related to Parkinson's disease.
Methodology
Mice were vaccinated with BCG or saline before being treated with MPTP, and various assays were conducted to measure dopamine levels and microglial activation.
Potential Biases
Potential bias in the interpretation of results due to the animal model used.
Limitations
The study was conducted in mice, and results may not directly translate to humans.
Participant Demographics
Male C57BL/6J mice, 8–10 weeks old.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website